Abstract
Purpose Evaluation of hemodynamics is crucial to predict growth and rupture of cerebral aneurysms. Variational data assimilation (DA) is a powerful tool to characterize patient-specific intra-aneurysmal flows. The DA method inversely estimates a boundary condition in fluid equations using personalized flow data; however, its high computational cost in optimization problems makes its use impractical. This study proposes a practical DA approach to evaluate patient-specific intra-aneurysmal flows.
Methods To estimate personalized flows, a variational DA method was combined with computational fluid dynamics (CFD) analysis and observed intra-aneurysmal velocity data, and an inverse problem was solved to estimate the spatiotemporal velocity profile at a boundary of the aneurysm neck. To circumvent an ill-posed inverse problem, model order reduction based on a Fourier series expansion was used to describe temporal changes in state variables.
Results In numerical validation using synthetic data from a direct CFD analysis, the present DA method achieved excellent agreement with the ground truth, with a velocity mismatch of approximately 18%. In flow estimations for three patient-specific datasets, the velocity mismatch for the present DA method was markedly lower than that for the direct CFD analysis and would mitigate unphysical velocity distributions in flow data from phase contract magnetic resonance imaging.
Conclusion By focusing only on the intra-aneurysmal region, the present DA approach provides an attractive way to evaluate personalized flows in aneurysms with greater reliability than conventional CFD and better efficiency than existing DA approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the MEXT Program for Promoting Researches on the Supercomputer Fugaku (Development of human digital twins for cerebral circulation using Fugaku, JPMXP1020230118). This work was also supported by JSPS KAKENHI Grant Number JP22H00190.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committees for human research at Shiga University of Medical Science (IRB Number: R2019-227).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
